Aclarion Expands Immediate Nociscan Access to New York City with Addition of Tenth Key Opinion Leader, Consultant Surgeon Roger Hartl, MD

Dr. Hartl is the Hansen-MacDonald Professor of Neurological Surgery and director of Spinal Surgery at the Weill Cornell Brain and Spine Center in New York, and co-director of New York-Presbyterian Och Spine.

Dr. Hartl becomes Aclarion’s 2^NL KOL to gain access to an MRI center authorized to perform Nociscans, adding NYC to Denver as the second active KOL location.

Aclarion will report on year-to-date Nociscan volumes before year-end and add this key metric to quarterly reporting starting in 2024.

BROOMFIELD, CO, November 6, 2023 (GLOBE NEWSWIRE) – via NewMediaWire — Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that uses biomarkers and proprietary enhanced intelligence algorithms to help physicians identify the location of chronic low back pain, today announced that Roger Hartl, MD, Hansen-MacDonald Professor of Neurological Surgery and director of Spinal Surgery at Weill Cornell Brain and Spine Center in New York, as well as New York-Presbyterian co-director Och Spine, will advise the company nationally as a key thought leader (KOL).

The practice of Dr. Hartl emphasizes an interdisciplinary approach to disease processes, and he works very closely with other specialists to personalize patients’ treatments. “My clinical interests focus on simple and complex spine surgery for degenerative conditions, as well as biological approaches for intervertebral disc repair and regeneration,” said Dr. Hartl. “Aclarion’s technology addresses a major gap in the current diagnosis of discogenic low back pain. I expect that Nociscan will provide valuable, objective information for our interdisciplinary approach to the treatment of degenerative intervertebral discs. Furthermore, I believe Nociscan will be equally valuable in our efforts to better understand less invasive surgical and biological treatment strategies for degenerative diseases of the spine.”

Chronic low back pain (cLBP) is a leading cause of opioid addiction in the US and the most expensive diagnosis in the United States. Aclarion’s Nociscan solution is the first science-based SaaS platform that helps physicians non-invasively distinguish between painful and non-painful intervertebral discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers shown to be associated with disc pain. Biomarker data is fed into proprietary algorithms to indicate whether a disc may be a source of pain. When combined with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving clinicians clarity to optimize treatment strategies.

“Dr. Hartl is a world-renowned neurosurgeon who continues to make advances in the diagnosis and treatment of low back pain,” said Brent Ness, CEO of Aclarion. “With immediate access to a Nociscan-activated MRI on Park Avenue in New York City, Dr. Hartl is already using Nociscan and will continue to gain clinical insights into the condition of his patients well into the future.”

Over the past 18 months, Aclarion has built a leading consortium of 10 KOL surgeons. Dr. Hartl represents the 10^e and latest KOL addition to Aclarion’s panel. The company is now in the critical phase of activating MRIs for each of its KOLs so they can begin using the technology, track clinical outcomes, and advocate for payer coverage decisions to expand access to Nociscan for all expand patients. The company will announce additional MRI activations for the remaining KOLs as they become available and will begin reporting on scan volumes as Nociscan usage increases with these MRI activations.

For information about using Nociscan in New York City, please contact Aclarion at info@aclarion.com.

About Aclarion, Inc.

Aclarion is a healthcare technology company that uses magnetic resonance spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers and enhanced intelligence algorithms to optimize clinical treatments. The company is entering the chronic low back pain market for the first time with Nociscan, the first evidence-based SaaS platform that helps physicians non-invasively distinguish between painful and non-painful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers shown to be associated with disc pain. Biomarker data is fed into proprietary algorithms to indicate whether a disc may be a source of pain. When combined with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving clinicians clarity to optimize treatment strategies. For more information please visit www.aclarion.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on management’s current plans and expectations and are subject to a number of uncertainties and risks that could materially affect the company’s current plans and expectations, as well as its future results of operations and financial condition. These and other risks and uncertainties are discussed in more detail in our filings with the Securities and Exchange Commission. Readers are encouraged to read the section entitled “Risk Factors” in the Company’s April 21, 2022 Prospectus as filed with the Securities and Exchange Commission on April 25, 2022 under Rule 424(b)(4), as well as other disclosures. included in the Prospectus and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor contacts:
Kirin M. Smith
PCG Advice, Inc.
646.823.8656
ksmith@pcgadvisory.com

Media contacts:
Jodi Lamberti
SPRIG advice
612.812.7477
jodi@sprigconsulting.com